Acusphere was listed on NASDAQ in 2003.
Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.
AAA was listed on NASDAQ in 2015, then acquired by Novartis for $3.9 billion in 2017.
Agensys was acquired by Astellas for up to $537 million in 2007.
Allenawas listed on NASDAQ in 2017.
Alydia was acquired by Organon for up to $240 million in 2021.
Anadys Pharmaceuticals was listed on NASDAQ in 2004.
AnaptysBio, Inc. was listed on NASDAQ in 2017.
Anthera was listed on NASDAQ in 2010.
APR Applied Pharma Research was acquired by Relief Therapeutics for CHF66.5M on Jun 29, 2021.
Aptinyx was listed on NASDAQ in 2018.
Arcutis was listed on NASDAQ in 2020.
ARMO Biosciences was acquired by Eli Lilly for 1.6 billion in May 2018 .
Arpida was listed on SIX Swiss Exchange in 2005.
Apreva was listed on NASDAQ in 2005 and acquired by Galenica in 2007 for $915 million.
Asthmatx was sold to Boston Scientific for up to $443 million in 2010.
Axovan was acquired by Actelion in 2004 for up to CHF252 million.
BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.
Basilea was listed on SIX Swiss Exchange in 2004.
BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system.
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant
Biovitrum was listed on OMX Stockholm in 2006. In 2010 Biovitrum and Swedish Orphan merged forming Swedish Orphan Biovitrum.
Brahms was acquired by ThermoFischer for $470 million in 2009.
C4 Therapeutics was listed on NASDAQ in 2020.
Cardion was acquired by Roche in 2003.
ChemoCentryx was listed on NASDAQ in 2012.
China Nuokang was listed on NASDAQ in 2009.
Connect Biopharma was listed on NASDAQ in 2021.
Corgentech was listed on NASDAQ in 2004.
Corvidia was acquired by Novo Nordisk for up to $2.1 billion in 2020.
Curetis was listed on Euronext in 2015 and then merged with NASDQ listed OpGen in 2019.
Cytokinetics was listed on NASDAQ in 2004.
Cytos was listed on SIX Swiss Exchange in 2002.
Delenex was acquired by Cell Medica in 2016.
Eiger BioPharmaceuticals was listed on NASDAQ in 2016.
Ellipse Technologies was acquired by NuVasive (Nasdaq: NUVA) in 2016.
Enanta was listed on NASDAQ in 2013.
Esbatech was acquired by Alcon (Novartis) for up to $589 million.
Everest Medicines was listed on the Hong Kong Stock Exchange in 2020.
Forbius was acquired by Bristol-Myers Squibb in 2020.
Galecto was listed on NASDAQ in 2020.
Galera was listed on NASDAQ in 2019.
Gemin X was acquired by Cephalon for $225 million in 2003.
Homology was listed on NASDAQ in 2018.
Icagen was listed on NASDAQ in 2004.
Infinity Pharmaceuticals was listed on NASDAQ in 2006.
InstilBio was listed on NASDAQ in 2021.
Interventional Spine was acquired DePuy Synthes in 2017.
iTeos was listed on NASDAQ in 2020.